腫瘍診断の世界市場

本レポートは、腫瘍診断市場とその競争環境を分析しています。複数の主要企業のプロフィール（収益、製品ポートフォリオ、最近の活動を含む）も検証しています。市場動向（牽引要因、制約、課題、機会など）を分析し、現在の市場規模と潜在的な市場規模について考察しています。本レポートは、業界企業が製品やサービスの生産およびライセンス供与について、情報に基づいた意思決定を行うのに役立ちます。

Report Highlights

The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.

腫瘍診断の世界市場は、2024年から2029年にかけて年平均成長率（CAGR）5.5%で増加し、2024年の776億ドルから2029年には1,015億ドルに達すると予測されています。

Report Scope

This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.

The market is divided into the following segments: diagnostic imaging, tumor biomarker tests, endoscopy, biopsy, hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), next generation sequencing (NGS) and others (cytology, microarrays, exosomes, flow cytometry, sanger sequencing, pyrosequencing etc.). The market is segmented by application into breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer and other cancers (lip, oral/cavity, liver/gallbladder, pancreas, melanoma, kidney, bladder, brain, central nervous system, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and leukemia). By end user, the market is segmented into hospitals/cancer centers/clinics, diagnostic imaging centers/reference laboratories, and other end users (physician offices, research, academic institutes, national cancer registries and contract research organizations).

Regional market analysis is provided for North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report also provides country-level analyses of markets and market segments. North America comprises the U.S., Canada and Mexico, while South America includes Brazil, Argentina and the rest of South America. In Europe, major countries covered are Germany, France, the U.K., Italy and Spain, along with the rest of Europe, which includes Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia and others. The Asia-Pacific region consists of Japan, China and India, as well as the rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, the Philippines, South Korea, Indonesia etc.), and the Middle East and Africa.

The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.

Report Synopsis

Report Includes

– 94 data tables and 59 additional tables

– Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029

– Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region

– Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables

– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses

– Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends

– Evaluation of recent patent activity featuring key granted and published patents

– Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

– Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Market Dynamics and Growth Factors

Emerging Technologies

Segmental Analysis

Regional Analysis

Strategic Initiatives

Conclusion

Chapter 2 Market Overview

Overview

Macroeconomic Factors Analysis

Impact of the U.S.-China Trade War

Porter’s Five Forces Analysis in the Oncology Market

Potential of New Entrants (Moderate to Low)

Bargaining Power of Suppliers (Moderate to High)

Bargaining Power of Buyers (Moderate to High)

Threat of Substitute Products or Services (Low)

Industry Rivalry (High)

Chapter 3 Market Dynamics

Key Takeaways

Market Drivers

Rising Incidence of Cancer Cases

Demand for Earlier Intervention and Preventive Diagnostic Screening

Growing Adoption of Companion Diagnostics

Increasing Aging Population Worldwide

Market Opportunities

Expanding Cancer Screening

Enhancing Access to Advanced Technologies

Market Restraints

Complex Reimbursement Policies

Lack of Cancer Awareness

Cost of Oncology Diagnostic Tests

Turnaround Time of Oncology Diagnostics

Market Challenges

Lack of Skilled Professionals

Complex Sample Preparation and Handling

Chapter 4 Regulatory Landscape

Market Regulations, by Top Country/Region

The U.S.

Europe

Japan

China

Chapter 5 Emerging Technologies and Developments

Emerging Technologies

AI in Oncology Diagnostics

Multi-Cancer Early Detection (MCED)

Theranostics

Digital Pathology and AI Integration

Patent Analysis

Key Takeaways

Chapter 6 Oncology Diagnostics Market

Segment Breakdown

Global Market Insights

Market Breakdown by Product Type

Diagnostics Imaging

Endoscopy Devices

Tumor Biomarker Tests

Biopsy Devices

Hematoxylin and Eosin

Immunohistochemistry

In situ Hybridization

Polymerase Chain Reaction

Next-Generation Sequencing

Others

Market Breakdown by Application

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Gastric Cancer

Other Applications

Market Breakdown by End User

Hospitals, Cancer Centers and Clinics

Diagnostic Imaging and Reference Laboratories

Others

Geographic Breakdown

Market Breakdown, by Region

Key Takeaways

North America

Europe

Asia-Pacific

South America

Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

Company Share Analysis

Strategic Initiatives

Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective

Introduction to ESG

ESG Performance Analysis

Environmental Performance

Social Performance

Governance Performance

Concluding Remarks from BCC

Chapter 9 Appendix

Research Methodology

References

Abbreviations

Company Profiles

ABBOTT

AGILENT TECHNOLOGIES INC.

BD

BIOMERIEUX

BIO-RAD LABORATORIES INC.

DANAHER CORP.

1. HOFFMANN-LA ROCHE LTD.

GE HEALTHCARE

ILLUMINA INC.

KONINKLIJKE PHILIPS N.V.

MERCK KGAA

MYRIAD GENETICS INC.

QIAGEN

SIEMENS HEALTHINEERS AG

THERMO FISHER SCIENTIFIC INC.

ZYTOVISION GMBH

Other Emerging Players in the Oncology Diagnostics Market

List of Tables

Summary Table : Global Market for Oncology Diagnostics, by Product Type, Through 2029

Table 1 : Global Incidence of All Cancer Cases, by WHO Region, 2022-2045

Table 2 : Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022

Table 3 : Cancer Treatments Based on Specific Tests

Table 4 : Select FDA-Approved AI-Associated/Associable-Equipped Medical Devices

Table 5 : Selected Patent Grants in Oncology Diagnostics, 2023-2025

Table 6 : Global Oncology Diagnostics Market, by Product Type, Through 2029

Table 7 : Global Diagnostics Imaging Market, by Region, Through 2029

Table 8 : Global Endoscopy Market, by Region, Through 2029

Table 9 : Global Tumor Biomarker Tests Market, by Region, Through 2029

Table 10 : Global Biopsy Devices Market, by Region, Through 2029

Table 11 : Global H&E and Special Stains Diagnostics Market, by Region, Through 2029

Table 12 : Global IHC Oncology Diagnostics Market, by Region, Through 2029

Table 13 : Global ISH Oncology Diagnostics Market, by Region, Through 2029

Table 14 : Global PCR Oncology Diagnostics Market, by Region, Through 2029

Table 15 : Global NGS Oncology Diagnostics Market, by Region, Through 2029

Table 16 : Global Other Oncology Diagnostics Tests Market, by Region, Through 2029

Table 17 : Global Oncology Diagnostics Market, by Application, Through 2029

Table 18 : Global Breast Cancer Diagnostics Market, by Region, Through 2029

Table 19 : Global Lung Cancer Diagnostics Market, by Region, Through 2029

Table 20 : Global Colorectal Cancer Diagnostics Market, by Region, Through 2029

Table 21 : Global Prostate Cancer Diagnostics Market, by Region, Through 2029

Table 22 : Global Gastric Cancer Diagnostics Market, by Region, Through 2029

Table 23 : Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029

Table 24 : Global Oncology Diagnostics Market, by End User, Through 2029

Table 25 : Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029

Table 26 : Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029

Table 27 : Global Oncology Diagnostics Market in Other End Uses, Through 2029

Table 28 : Global Oncology Diagnostics Market, by Region, Through 2029

Table 29 : North American Oncology Diagnostics Market, by Country, Through 2029

Table 30 : U.S. Oncology Diagnostics Market, by Product Type, Through 2029

Table 31 : U.S. Oncology Diagnostics Market, by Application, Through 2029

Table 32 : U.S. Oncology Diagnostics Market, by End User, Through 2029

Table 33 : Canadian Oncology Diagnostics Market, by Product Type, Through 2029

Table 34 : Canadian Oncology Diagnostics Market, by Application, Through 2029

Table 35 : Canadian Oncology Diagnostics Market, by End User, Through 2029

Table 36 : Mexican Oncology Diagnostics Market, by Product Type, Through 2029

Table 37 : Mexican Oncology Diagnostics Market, by Application, Through 2029

Table 38 : Mexican Oncology Diagnostics Market, by End User, Through 2029

Table 39 : European Oncology Diagnostics Market, by Country, Through 2029

Table 40 : Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022

Table 41 : German Oncology Diagnostics Market, by Product Type, Through 2029

Table 42 : German Oncology Diagnostics Market, by Application, Through 2029

Table 43 : German Oncology Diagnostics Market, by End User, Through 2029

Table 44 : Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022

Table 45 : French Oncology Diagnostics Market, by Product Type, Through 2029

Table 46 : French Oncology Diagnostics Market, by Application, Through 2029

Table 47 : French Oncology Diagnostics Market, by End User, Through 2029

Table 48 : New Cases of Cancer Diagnosed Each Year in the U.K., 2021

Table 49 : The U.K. Oncology Diagnostics Market, by Product Type, Through 2029

Table 50 : The U.K. Oncology Diagnostics Market, by Application, Through 2029

Table 51 : The U.K. Oncology Diagnostics Market, by End User, Through 2029

Table 52 : Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022

Table 53 : Italian Oncology Diagnostics Market, by Product Type, Through 2029

Table 54 : Italian Oncology Diagnostics Market, by Application, Through 2029

Table 55 : Italian Oncology Diagnostics Market, by End User, Through 2029

Table 56 : Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022

Table 57 : Spanish Oncology Diagnostics Market, by Product Type, Through 2029

Table 58 : Spanish Oncology Diagnostics Market, by Application, Through 2029

Table 59 : Spanish Oncology Diagnostics Market, by End User, Through 2029

Table 60 : Rest of European Countries’ Oncology Diagnostics Market, by Product Type, Through 2029

Table 61 : Rest of European Countries’ Oncology Diagnostics Market, by Application, Through 2029

Table 62 : Rest of European Countries’ Oncology Diagnostics Market, by End User, Through 2029

Table 63 : Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029

Table 64 : Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022

Table 65 : Chinese Oncology Diagnostics Market, by Product Type, Through 2029

Table 66 : Chinese Oncology Diagnostics Market, by Application, Through 2029

Table 67 : Chinese Oncology Diagnostics Market, by End User, Through 2029

Table 68 : Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022

Table 69 : Japanese Oncology Diagnostics Market, by Product Type, Through 2029

Table 70 : Japanese Oncology Diagnostics Market, by Application, Through 2029

Table 71 : Japanese Oncology Diagnostics Market, by End User, Through 2029

Table 72 : Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022

Table 73 : Indian Oncology Diagnostics Market, by Product Type, Through 2029

Table 74 : Indian Oncology Diagnostics Market, by Application, Through 2029

Table 75 : Indian Oncology Diagnostics Market, by End User, Through 2029

Table 76 : Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029

Table 77 : Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029

Table 78 : Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029

Table 79 : South American Oncology Diagnostics Market, by Country, Through 2029

Table 80 : Brazilian Oncology Diagnostics Market, by Product Type, Through 2029

Table 81 : Brazilian Oncology Diagnostics Market, by Application, Through 2029

Table 82 : Brazilian Oncology Diagnostics Market, by End User, Through 2029

Table 83 : Argentine Oncology Diagnostics Market, by Product Type, Through 2029

Table 84 : Argentine Oncology Diagnostics Market, by Application, Through 2029

Table 85 : Argentine Oncology Diagnostics Market, by End User, Through 2029

Table 86 : Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029

Table 87 : Rest of South American Oncology Diagnostics Market, by Application, Through 2029

Table 88 : Rest of South American Oncology Diagnostics Market, by End User, Through 2029

Table 89 : Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029

Table 90 : Middle East and African Oncology Diagnostics Market, by Application, Through 2029

Table 91 : Middle East and African Oncology Diagnostics Market, by End User, Through 2029

Table 92 : Company Shares in the Oncology Diagnostics Market, 2023

Table 93 : ESG: Environmental Overview

Table 94 : ESG: Social Overview

Table 95 : ESG: Governance Overview

Table 96 : Abbreviations Used in this Report

Table 97 : Abbott: Company Snapshot

Table 98 : Abbott: Financial Performance, FY 2022 and 2023

Table 99 : Abbott: Product Portfolio

Table 100 : Agilent Technologies Inc.: Company Snapshot

Table 101 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024

Table 102 : Agilent Technologies Inc.: Product Portfolio

Table 103 : Agilent Technologies Inc.: News/Key Developments, 2024

Table 104 : BD: Company Snapshot

Table 105 : BD: Financial Performance, FY 2023 and 2024

Table 106 : BD: Product Portfolio

Table 107 : bioMerieux: Company Snapshot

Table 108 : bioMerieux: Financial Performance, FY 2022 and 2023

Table 109 : bioMerieux: Product Portfolio

Table 110 : Bio-Rad Laboratories Inc.: Company Snapshot

Table 111 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024

Table 112 : Bio-Rad Laboratories Inc.: Product Portfolio

Table 113 : Danaher Corp.: Company Snapshot

Table 114 : Danaher Corp.: Financial Performance, FY 2022 and 2023

Table 115 : Danaher Corp.: Product Portfolio

Table 116 : Danaher Corp.: News/Key Developments, 2023

Table 117 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 118 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024

Table 119 : F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 120 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025

Table 121 : GE HealthCare: Company Snapshot

Table 122 : GE HealthCare: Financial Performance, FY 2023 and 2024

Table 123 : GE HealthCare: Product Portfolio

Table 124 : GE HealthCare: News/Key Developments, 2024

Table 125 : Illumina Inc.: Company Snapshot

Table 126 : Illumina Inc.: Financial Performance, FY 2023 and 2024

Table 127 : Illumina Inc.: Product Portfolio

Table 128 : Illumina Inc.: News/Key Developments, 2024

Table 129 : Koninklijke Philips N.V.: Company Snapshot

Table 130 : Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024

Table 131 : Koninklijke Philips N.V.: Product Portfolio

Table 132 : Merck KGaA: Company Snapshot

Table 133 : Merck KGaA: Financial Performance, FY 2022 and 2023

Table 134 : Merck KGaA: Product Portfolio

Table 135 : Myriad Genetics Inc.: Company Snapshot

Table 136 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023

Table 137 : Myriad Genetics Inc.: Product Portfolio

Table 138 : Myriad Genetics Inc.: News/Key Developments, 2025

Table 139 : Qiagen: Company Snapshot

Table 140 : Qiagen: Financial Performance, FY 2022 and 2023

Table 141 : Qiagen: Product Portfolio

Table 142 : Siemens Healthineers AG: Company Snapshot

Table 143 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024

Table 144 : Siemens Healthineers AG: Product Portfolio

Table 145 : Siemens Healthineers AG: News/Key Developments, 2024

Table 146 : Thermo Fisher Scientific Inc.: Company Snapshot

Table 147 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023

Table 148 : Thermo Fisher Scientific Inc.: Product Portfolio

Table 149 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023

Table 150 : ZytoVision GmbH: Company Snapshot

Table 151 : ZytoVision GmbH: Product Portfolio

Table 152 : Emerging Startups in Oncology Diagnostics Market

List of Figures

Summary Figure : Global Market Shares of Oncology Diagnostics, by Product Type, 2023

Figure 1 : Porter’s Five Forces Analysis of the Oncology Market

Figure 2 : Market Dynamics of Oncology Diagnostics

Figure 3 : Global Incidence Shares of All Cancer Cases, by Region, 2022

Figure 4 : Number of FDA-Approved Companion Diagnostic Devices, 1997–2024

Figure 5 : Emerging Trends and Technologies in Oncology Diagnostics

Figure 6 : Share of Global Market for Oncology Diagnostics, by Product Type, 2023

Figure 7 : Share of Global Market for Oncology Diagnostics, by Application, 2023

Figure 8 : Shares of Global Market for Oncology Diagnostics, by End User, 2023

Figure 9 : Share of Global Market for Oncology Diagnostics, by Region, 2023

Figure 10 : Share of North American Market for Oncology Diagnostics, by Country, 2023

Figure 11 : Share of European Market for Oncology Diagnostics, by Country, 2023

Figure 12 : Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022

Figure 13 : Cervical Cancer Screening Rates in European Countries, 2022

Figure 14 : Colorectal Cancer Screening Rates in European Countries, 2022

Figure 15 : Current and Forecasted Cancer Prevalence in the U.K., 2020-2040

Figure 16 : Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022

Figure 17 : Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022

Figure 18 : Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023

Figure 19 : Share of South American Market for Oncology Diagnostics, by Country, 2023

Figure 20 : Share of the Global Market for Oncology Diagnostics, by Company, 2023

Figure 21 : ESG Pillars

Figure 22 : Advantages of ESG for Companies

Figure 23 : Abbott: Revenue Share, by Business Unit, FY 2023

Figure 24 : Abbott: Revenue Share, by Country/Region, FY 2023

Figure 25 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024

Figure 26 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024

Figure 27 : BD: Revenue Share, by Business Unit, FY 2024

Figure 28 : BD: Revenue Share, by Country/Region, FY 2024

Figure 29 : bioMerieux: Revenue Share, by Business Unit, FY 2023

Figure 30 : bioMerieux: Revenue Share, by Region, FY 2023

Figure 31 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024

Figure 32 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024

Figure 33 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023

Figure 34 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023

Figure 35 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024

Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024

Figure 37 : GE HealthCare: Revenue Share, by Business Unit, FY 2024

Figure 38 : GE HealthCare: Revenue Share, by Country/Region, FY 2024

Figure 39 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024

Figure 40 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024

Figure 41 : Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024

Figure 42 : Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023

Figure 43 : Merck KGaA: Market Share, by Business Unit, 2023

Figure 44 : Merck KGaA: Revenue Share, by Country/Region, 2023

Figure 45 : Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023

Figure 46 : Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023

Figure 47 : Qiagen: Revenue Share, by Business Unit, FY 2023

Figure 48 : Qiagen: Revenue Share, by Country/Region, FY 2023

Figure 49 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024

Figure 50 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024

Figure 51 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023

Figure 52 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自律型無人潜水機の2030年までの世界市場 2025-06-06
• 世界のSDV(ソフトウェア・デファインド・ビークル)市場 2025-06-06
• 高分子発泡体の世界市場 2025-06-06
• 世界の細胞株と細胞膜市場 2025-06-05
• 世界のエッジAI市場 2025-06-03

BCC Research  出版レポート一覧